Recent advances in managing chronic HCV infection: Focus on therapy in patients with severe liver disease by Maan, R. (Raoel) & Meer, A.J.P. (Adriaan) van der
F1000Research
Open Peer Review
F1000 Faculty Reviews are commissioned
from members of the prestigious F1000
. In order to make these reviews asFaculty
comprehensive and accessible as possible,
peer review takes place before publication; the
referees are listed below, but their reports are
not formally published.
, MedizinischeThomas von Hahn
Hochschule Hannover Germany, German
Center for Infection Research Germany,
Medizinische Hochschule Hannover
Germany
, The Institute of ViralThomas F. Baumert
and Liver Disease and the University of
Strasbourg France
, University Clinic LeipzigThomas Berg
Germany
Discuss this article
 (0)Comments
3
2
1
REVIEW
Recent advances in managing chronic HCV infection: focus on
 therapy in patients with severe liver disease [version 1; referees:
3 approved]
Raoel Maan, Adriaan J. van der Meer
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, 3015, Netherlands
Abstract
Chronic hepatitis C virus (HCV) infection still represents a major public health
problem, as it is thought to be responsible for more than 350,000 deaths
around the globe on a yearly basis. Fortunately, successful eradication of the
virus has been associated with improved clinical outcome and reduced
mortality rates. In the past few years, treatment has improved considerably by
the implementation of direct-acting antivirals (DAAs). From 2014 onwards,
sofosbuvir, simeprevir, daclatasvir, ledipasvir, paritaprevir, ombitasvir, and
dasabuvir have been approved by the US Food and Drug Administration (FDA)
and European Medicines Agency (EMA). Regimens with various combinations
of these new drugs, without the use of interferon (IFN), proved to be very
effective and well tolerated, even among patients with advanced liver disease.
Moreover, treatment duration could be shortened to 12 weeks in the majority of
patients. The high costs of these DAAs, however, limit the availability of
IFN-free therapy worldwide. Even in wealthy countries, it is deemed necessary
to prioritize DAA treatment in order to limit the immediate impact on the health
budget. As patients with advanced liver disease are in most need of HCV
clearance, many countries decided to treat those patients first. In the current
review, we focus on the currently available IFN-free treatment options for
patients with cirrhosis. We discuss the virological efficacy as well as the clinical
relevance of these regimens among this specific patient population.
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Natural history
Chronic hepatitis C virus (HCV) infection continues to be a major 
global public health problem, with recent estimates suggesting that 
64–103 million people are infected worldwide1. Chronic infection 
leads to slowly progressive hepatic fibrosis, which may eventually 
lead to cirrhosis2,3. Once cirrhosis is established, patients have an 
increased risk of developing complications such as ascites, sponta-
neous bacterial peritonitis, hepatic encephalopathy, variceal bleed-
ing, and hepatocellular carcinoma (HCC). Although the incidence 
of HCV infection is declining in the West, it has been estimated 
that the incidence of patients with HCV-induced cirrhosis will not 
peak until 20304. At the moment, chronic HCV infection is already 
the leading indication for liver transplantation in many Western 
countries5. Not to be forgotten, however, is that the natural history 
of chronic HCV infection extends beyond the liver as well. Before 
the stage of cirrhosis, there may already be extrahepatic manifesta-
tions that impair the patient’s health-related quality of life (HRQoL), 
of which fatigue is most frequently reported (approximately 50% 
of patients)6–8. In terms of solid clinical endpoints, patients are at 
increased risk of diabetes mellitus, renal failure, cardiovascular 
events, and malignant lymphoma9. The impaired overall survival 
among those with chronic HCV infection is thus the result of an 
increase in both liver-related as well as non-liver-related deaths, as 
was recently highlighted in an unique natural history study from 
Taiwan which included 19,636 participants who were followed for 
a mean duration of 16.2 years10.
Antiviral therapy
Before 2011, treatment for chronic HCV infection depended on 
the administration of pegylated interferon alpha (PegIFN) and 
ribavirin (RBV), which was accompanied by the occurrence of 
many side effects such as flu-like symptoms, depression, and cyto-
penias. These side effects were bothersome, especially because the 
IFN-based regimens had a limited chance of attaining a sustained 
virological response (SVR [HCV RNA negativity in the circulation 
12–24 weeks after cessation of antiviral therapy]). If physicians 
were not already reluctant to treat out of fear for severe adverse 
events in the specific population of patients with advanced liver dis-
ease, PegIFN and RBV were often unsuccessful. In patients with 
compensated cirrhosis, SVR rates ranged from 10 to 44% for HCV 
genotypes 1 and 4 and 33 to 72% for HCV genotypes 2 and 3. When 
patients were known to have decompensated cirrhosis, SVR rates 
even dropped to 0–16% for HCV genotypes 1 and 4 and 44–57% 
for HCV genotypes 2 and 311. However, because of safety issues, 
IFN therapy, in case of unstable liver disease, was mostly restricted 
to specialized centers. As a result, many patients were unable to 
attain an SVR, which is considered to be the marker for viral clear-
ance based on its long-term durability12.
The successful development of protease inhibitors for the treatment 
of the human immunodeficiency virus initiated the development of 
the first direct-acting antivirals (DAAs) for the treatment of HCV 
infection. In 2011, the protease inhibitors telaprevir and boceprevir 
were the first DAAs to be introduced. When added to PegIFN and 
RBV, the duration of therapy could be halved to 24–28 weeks in 
about 50% of patients, while SVR rates improved substantially in 
both treatment-naïve and treatment-experienced patients with HCV 
genotype 113–17. Unfortunately, among those with cirrhosis, the 
treatment duration could not be easily reduced and the improvement 
in the rate of SVR was only limited with an increase to approxi-
mately 50%. The downsides include the following: these first two 
DAAs were not very effective against HCV genotypes other than 
genotype 1; treatment became more complex with various dos-
ing schedules, durations, and stopping rules; the pill burden was 
large; the rates of resistance-associated variants (RAVs) were high; 
and there were many potential drug-drug interactions. Moreover, 
the first real-world data raised important safety issues, especially 
among patients with compensated cirrhosis, and PegIFN remained a 
necessity18. The development of antiviral therapy has moved at an 
incredible pace during the 3 years following the first proof-of-concept 
that chronic HCV infection could be eradicated without PegIFN19. 
At the moment, IFN-free regimens, in which multiple classes of 
DAAs are combined, revolutionize the treatment of chronic HCV 
infection. Short and well-tolerated regimens have reported SVR 
rates of around 95%, even among patients with cirrhosis20–24. Unfor-
tunately, the high costs of the DAAs currently make these drugs 
unavailable for the majority of patients worldwide. Also, in wealthy 
countries it is deemed necessary to prioritize DAA treatment in order 
to limit the immediate impact on the health budget, even though 
modeling data indicated that the IFN-free regimens are cost effec-
tive in the long term. As a consequence, physicians are often limited 
to treat only those patients with advanced liver disease, the specific 
population on which we will focus in the current review.
Life cycle of the hepatitis C virus
Hepatitis C virus is a small enveloped virus of approximately 
55–65 nanometers in size and is a member of the genus Hepacivirus, 
belonging to the Flaviviridae family. It contains a single-stranded 
RNA genome of positive polarity. This genome is approximately 
9600 nucleotides in length and consists of a highly conserved 
59 untranslated region, followed by a single open reading frame 
that encodes a polyprotein of 3010 to 3033 amino acids. Cellular 
and viral proteases cleave this large protein into ten smaller viral 
gene products: three structural proteins (core, E1, and E2); an ion 
channel (p7); and six nonstructural proteins (NS2, NS3A, NS4A, 
NS4B, NS5A, and NS5B) (Figure 1). Structural proteins are 
required for assembly and are used for the determination of the 
seven main HCV genotypes (and subgenotypes)5. The p7 and NS2 
protease are required for the release of infectious particles. The other 
nonstructural proteins (NS3A, NS4A, NS4B, NS5A, and NS5B) are 
closely involved in HCV replication25. NS3 and its cofactor NS4A 
form a stable heterodimeric complex, which cleaves the HCV 
polyprotein at four sites. NS4B is the presumed central organizer 
of the HCV replicase complex and a main inducer of intracellular 
membrane rearrangements. The NS5A protein is essential for RNA 
replication and assembly of infectious virus particles. The RNA- 
dependent NS5B protein is the RNA polymerase catalyzing the 
amplification of the viral RNA genome25,26. Figure 2 shows the entry 
of HCV into the hepatocytes, as well as its life cycle and replication 
process26. In addition, several host factors have been involved in 
the HCV life cycle, which may represent new targets for antiviral 
treatment. These include epidermal growth factor receptor (EGFR) 
and ephrin receptor A2 (EphA2), which are two receptor tyrosine 
kinases that have recently been identified as HCV entry factors27. 
Another host factor, microRNA-122 (miR-122), is a hepatocyte-
abundant microRNA which binds to the 5’ untranslated region of 
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Figure 2. Life cycle of the hepatitis C virus. Adapted from Feeney et al.26. Schematic overview of the life cycle of the hepatitis C virus (HCV). 
In order to enter the hepatocyte, HCV interacts with co-receptors, resulting in its endocytosis. Then the virus fuses with the endosome and 
uncoats its RNA. Host ribosomes translate the RNA into a polyprotein, which is cleaved by host and virally encoded proteases into the three 
structural and seven non-structural proteins. The non-structural proteins form a complex on a “membranous web” that replicates HCV RNA. 
The Golgi assembles the HCV RNA with viral structural proteins, leading to the formation of infectious viral particles, which are exocytosed 
from the cell. © 2015 BMJ Publishing Group Ltd. All rights reserved.
Figure 1. The hepatitis C virus (HCV) genome. The hepatitis C virus (HCV) genome encoding three structural proteins and seven 
non-structural proteins. The direct-acting antivirals are listed below the proteins and include the NS3/4A (or protease) inhibitors, the NS5A 
inhibitors, and the NS5B polymerase inhibitors (both nucleosides and non-nucleosides). The direct-acting antivirals approved by the US Food 
and Drug Administration and the European Medicines Agency are highlighted in bold.
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the HCV genome. Hereby, it is thought to promote HCV RNA sta-
bility and accumulation and to protect the HCV genome from the 
innate immune response28. Cyclophilin A (CypA) is a protein that is 
involved in the replication of HCV by binding to the NS5A protein 
of all HCV genotypes29. Lastly, apolipoprotein E (apoE) is a com-
ponent of lipoviral particles, which is involved in the HCV infection 
of hepatocytes30.
Mechanism of action of antiviral drugs
Although still not fully elucidated, IFN is thought to induce 
a large number of genes (called IFN-stimulated genes) with 
antiviral properties, leading to a multi-faceted attack on the 
virus. In addition, it also has some direct antiviral actions as well 
as important interactions with the adaptive and innate immune 
responses31. RBV is a guanosine analogue with activity against 
several RNA and DNA viruses. Different hypotheses regarding 
its mechanism of action have been proposed, of which the theory 
of lethal mutagenesis seems most reasonable31. Protease inhibi-
tors target the NS3/4A serine protease and thereby inhibit the 
cleavage of this protein and thus HCV replication26. Current 
approved “-previrs” include telaprevir, boceprevir, simeprevir, 
and paritaprevir (Figure 1). The NS5A inhibitors, also known 
as “-asvirs”, target another nonstructural protein and block the 
replication of HCV RNA at the stage of membranous web 
biogenesis32. So far, daclatasvir, ledipasvir, and ombitasvir have 
been approved (Figure 1). Both NS3/4A protease inhibitors and 
NS5A inhibitors have very potent antiviral activity but exhibit a 
low barrier to viral resistance. The NS5B inhibitors, or “-buvirs”, 
can be divided into two main classes: nucleos(t)ide inhibitors and 
non-nucleotide inhibitors (Figure 1). By binding to the active site 
of the NS5B RNA-dependent RNA polymerase, nucleos(t)ide 
inhibitors (e.g., sofosbuvir) cause premature chain termination. The 
non-nucleotide inhibitors (e.g., dasabuvir) bind outside the active 
site, causing a conformational change, and thereby decrease the 
polymerase activity of the enzyme26.
Current treatment regimens
There are extensive data from phase III or IV studies on the 
efficacy of IFN-free regimens, but patients with compensated and 
decompensated cirrhosis were often underrepresented. Currently, 
more data are emerging from real-world studies on the efficacy of 
these regimens, which included patients with the most severe cir-
rhosis. Table 1–Table 4 show the data from phase III or IV studies 
available on the efficacy of IFN-free antiviral therapy. Below, we 
will discuss the treatment regimens in a more conceptual way for 
the treatment of patients with compensated cirrhosis.
Table 1. Rates of SVR for patients with compensated cirrhosis HCV genotype 1 (phase III/IV 
studies).
Regimen Duration Patients SVR rate Study (reference)
LDV – SOF ± RBV 12–24 weeks Naïve 97–100% ION-121
LDV – SOF ± RBV 12–24 weeks TE 82–100% ION-220
LDV – SOF 
LDV – SOF - RBV
24 weeks 
12 weeks
TE 
TE
97% 
96%
SIRIUS84
SIM – SOF 12 weeks Naïve 
TE
88% 
79%
OPTIMIST-222
SIM – SOF ± RBV 12 weeks Naïve 
TE
75% 
73–88%
Trio Network85
SIM – SOF ± RBV 12 weeks Naïve 
TE
87–93% 
80–82%
HCV-Target86
OMB – PAR/r – DSV + RBV 12–24 weeks Naïve 
TE
94–95% 
90–97%
TURQUOSE-II23
OMB – PAR/r – DSV 12 weeks TE 100% TURQUOSE-III24
GPV – ELB 12 weeks Naïve 97% C-EDGE87
SIM – SOF 12 weeks Naïve 
TE
95% 
92%
Pearlman et al.88
SIM – SOF 12 weeks Naïve 
TE
83% Aqel et al.89
SIM – SOF ± RBV 12 weeks Naïve 
TE
91–94% 
88–95%
Saxena et al.46
SIM – SOF 12 weeks Naïve and TE 87% Shiffman et al.90
DCV – ASV – BCV ± RBV 12 weeks Naïve and TE 87–98% Unity-291
VPV – SOF 12 weeks Naïve and TE 99% ASTRAL-145
a. Abbreviations: ASV, asunaprevir; BCV; beclabuvir; DCV, daclatasvir; DSV, dasabuvir; ELB, elbasvir; GPV, 
grazoprevir; HCV, hepatitis C virus; LDV, ledipasvir; OMB, ombitasvir; PAR/r, paritaprevir/ritonavir; RBV, ribavirin; 
SIM, simeprevir; SOF, sofosbuvir; SVR, sustained virological response; TE, treatment-experienced; VPV, 
velpatasvir
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Table 2. Rates of SVR for patients with compensated cirrhosis HCV genotype 2–4 (phase III/IV studies).
HCV Genotype Regimen Duration Patients SVR rate Study (reference)
HCV genotype 3 DCV – SOF 12 weeks Naïve and TE 58–97% ALLY-343
HCV genotype 2 
HCV genotype 3
SOF + RBV 12 weeks 
12 weeks
Naïve 91% 
34%
FISSION40
HCV genotype 2 
HCV genotype 3
SOF + RBV 12 weeks 
12 weeks
Naïve 94% 
21%
POSITRON39
HCV genotype 3 
HCV genotype 2 
HCV genotype 3
SOF + RBV 24 weeks 
12 weeks 
24 weeks
Naïve 
TE 
TE
92% 
78% 
62%
VALENCE92
HCV genotype 2 
 
HCV genotype 3 
 
HCV genotype 3
SOF + RBV 
 
 
16 weeks 
24 weeks 
16 weeks 
24 weeks 
16 weeks 
24 weeks
TE 
 
Naïve 
 
TE
87% 
100% 
57% 
82% 
47% 
76%
BOSON STUDY44 
 
 
HCV genotype 2 SOF + RBV 12 weeks Naïve 
TE
67% 
76%
Trio Network85
HCV genotype 2 
 
HCV genotype 3
SOF + RBV 
 
SOF + RBV
12 weeks 
16 weeks 
12 weeks 
16 weeks
TE 
 
TE
60% 
78% 
19% 
61%
FUSION39 
HCV genotype non-1 SOF – VPV 12 weeks Naïve and TE 100% ASTRAL-145
HCV genotype 2 SOF – VPV 12 weeks Naïve and TE 100% ASTRAL-293
HCV genotype 3 SOF – VPV 12 weeks Naïve and TE 91% ASTRAL-393
HCV genotype 3 DCV – SOF + RBV 12 weeks 
16 weeks
Naïve and TE 83% 
89%
ALLY-3+94
a. Abbreviations: DCV, daclatasvir; HCV, hepatitis C virus; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virological response; 
TE, treatment-experienced; VPV, velpatasvir
Table 3. Rates of SVR for patients with decompensated cirrhosis HCV genotype 1 
(phase III/IV studies).
Regimen Duration Patients SVR rate Study (reference)
LDV – SOF ± RBV 12 – 24 weeks Naïve and TE 86–89% SOLAR-182
LDV – SOF ± RBV 12 – 24 weeks Naïve and TE 84–92% SOLAR-295
SOF + RBV 
SIM – SOF 
SIM – SOF + RBV
12 weeks 
12 weeks 
12 weeks
Naïve and TE 
Naïve and TE 
Naïve and TE
52% 
74% 
66%
HCV-Target96
DCV – SOF + RBV 12 weeks Naïve and TE 56–94%* ALLY-197
LDV – SOF 
LDV – SOF + RBV 
DCV – SOF 
DCV – SOF + RBV
12 weeks 
12 weeks 
12 weeks 
12 weeks
Naïve and TE 
Naïve and TE 
Naïve and TE 
Naïve and TE
81% 
86% 
60%# 
82%
UK cohort EAP81 
SIM – SOF ± RBV 12 weeks Naïve and TE 69–79% Saxena et al.46
SIM – SOF ± RBV 12 weeks Naïve and TE 68% Aqel et al.89
SIM – SOF 12 weeks Naïve and TE 67–77% Shiffman et al.90
SIM – SOF 
SIM – SOF + RBV
12 weeks 
12 weeks
Naïve and TE 
Naïve and TE
52–65% 
44–65%#
Backus et al.98
SOF – VPV 
SOF – VPV + RBV 
SOF – VPV
12 weeks 
12 weeks 
24 weeks
Naïve and TE 88% 
96% 
92%
ASTRAL-499
a. Abbreviations: DCV, daclatasvir; HCV, hepatitis C virus; LDV, ledipasvir; RBV, ribavirin; SIM, 
simeprevir; SOF, sofosbuvir; SVR, sustained virological response; TE, treatment-experienced; VPV, 
velpatasvir
b. *Also included patients with HCV genotype 2, 3, and 4
c. #Fewer than 10 patients were included in a specific subgroup
Page 6 of 14
F1000Research 2016, 5(F1000 Faculty Rev):367 Last updated: 25 DEC 2016
HCV genotype 1
In the Western world, HCV genotype 1 is the most prevalent 
(>50%). The initial development of DAAs was therefore mainly 
focused on this genotype. Although IFN-free therapy is preferred, 
the combination of a second-generation NS3/4A protease inhibitor, 
a NS5A inhibitor, or a NS5B inhibitor with PegIFN and RBV for 
12–48 weeks has been assessed33–36. Although not approved, even 
the addition of a NS3/4A protease inhibitor and a NS5A inhibitor 
to PegIFN and RBV for 24 weeks could have been an option for the 
treatment of chronic HCV genotype 1 infection37. For patients who 
are unable to tolerate PegIFN, the combination of a NS5B inhibitor 
and RBV was assessed, but phase III studies were never performed 
due to the lack of efficacy. When focusing on the regimens that did 
reach SVR rates of more than 90%, the optimal regimen consists of 
at least two classes of DAAs, with or without the addition of RBV. 
The combination of a NS5B inhibitor with a NS5A inhibitor and/or 
a NS3/4A protease inhibitor is enough to create a high barrier to 
resistance20–22. In cirrhotic patients, some regimens show lack of 
efficacy, which could be improved by the addition of RBV and/or 
the extension of antiviral therapy to 24 weeks. As the development 
of novel DAAs is still ongoing, recent data have shown that second-
generation regimens, including a NS5A inhibitor and a NS3/4A 
protease inhibitor, may be equally effective for this genotype38. 
Thus, inclusion of a NS5B inhibitor may not be a necessity.
Since there is a difference in efficacy among patients with HCV 
genotype 1a and 1b, different regimens were applied among these 
patients23,24. RAVs that are present at baseline or emerge during 
antiviral therapy may account for this difference between the two 
subtypes. Therefore, before initiating most regimens, subtyping of 
the HCV genotype 1 is required. However, lower response rates in 
patients with HCV genotype 1a seem to be a problem only when 
a NS3/4A protease inhibitor is incorporated into the treatment 
regimen20,21,23. At the price of additional side effects, this effect may 
be partly overcome by adding RBV to the treatment regimen.
HCV genotype 2
Historically, patients with HCV genotype 2 were the easiest to treat, 
even when patients had cirrhosis. Currently, an IFN-free combina-
tion including a NS5B inhibitor and RBV seems sufficient to clear 
the virus39–41. When patients are intolerant to RBV, a regimen with a 
NS5B inhibitor and a NS5A inhibitor could be an attractive option, as 
both have antiviral activity against this genotype. This combination, 
however, has not been extensively investigated in clinical trials42.
HCV genotype 3
Patients with HCV genotypes 2 and 3 were found to be relatively 
IFN sensitive and required a shorter duration of therapy with 
lower doses of RBV to achieve higher rates of SVR as compared 
to patients with HCV genotypes 1 and 4. Even with PegIFN and 
RBV, however, HCV genotype 3 was more difficult to cure than 
genotype 2, particularly in patients with established cirrhosis. In 
the current IFN-free era, HCV genotype 3 has actually replaced 
HCV genotype 1 as the most challenging genotype. In contrast to 
its effect in non-cirrhotic patients with HCV genotype 3, the com-
bination of a NS5B inhibitor and RBV in cirrhotic patients is sub-
optimal and has a high virological relapse rate39–41. The addition of 
a NS5A inhibitor to this regimen could improve response rates, but 
the incremental efficacy of a 12-week regimen remains limited43. 
Although the duration has not been investigated within clinical tri-
als, current guidelines recommend a 24-week regimen including a 
NS5B inhibitor and a NS5A inhibitor with or without RBV. So far, 
none of the currently approved DAAs have optimal antiviral activ-
ity against HCV genotype 3, so the “re-introduction” of PegIFN 
for this genotype needs to be considered among those who are able 
to tolerate its side effects44. Recently, a pan-genotypic regimen for 
Table 4. Rates of SVR for patients with decompensated cirrhosis HCV genotype non-1 (phase III/IV studies).
HCV genotype Regimen Duration Patients SVR rate Study (reference)
HCV genotype 4 LDV – SOF ± RBV 12 – 24 weeks Naïve and TE 57–86% SOLAR-295
HCV genotype 2 
HCV genotype 3
SOF + RBV 12 weeks Naïve and TE 81% 
39%
HCV-Target96
HCV genotype 2 
HCV genotype 3 
HCV genotype 4
DCV – SOF + RBV 12 weeks Naïve and TE 80%# 
83%# 
100%#
ALLY-197
HCV genotype 3 
Other HCV genotypes 
than 1 and 3
LDV – SOF ± RBV 
DCV – SOF ± RBV 
LDV – SOF + RBV 
DCV – SOF ± RBV
All 12 weeks Naïve and TE 43–59%# 
70–71%# 
89% 
85–100%#
UK cohort EAP81 
HCV genotype 2 SOF + RBV 12 weeks Naïve and TE 44–71%# Backus et al.98
HCV genotype non-1 SOF – VPV 
SOF – VPV + RBV 
SOF – VPV
12 weeks 
12 weeks 
24 weeks
Naïve and TE 50–100%# 
85–100%# 
50–100%#
ASTRAL-499
a. Abbreviations: DCV, daclatasvir; HCV, hepatitis C virus; LDV, ledipasvir; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir; SVR, 
sustained virological response; TE, treatment-experienced
b.*Also included patients with HCV genotype 2, 3, and 4
c.#Fewer than 10 patients were included in a specific subgroup
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12 weeks, including a NS5B and NS5A inhibitor, seemed highly 
effective for HCV genotype 3, even among treatment-experienced 
patients with cirrhosis45.
HCV genotype 4
When PegIFN-based treatment was considered, patients with HCV 
genotype 4 used to be grouped with patients infected with HCV 
genotype 1. With the DAAs, these patients respond to the same 
regimens as well, and possibly even better. Although data in cir-
rhotic patients are scarce, due to the low prevalence of this genotype 
in most Western countries, the combination of a NS5B inhibitor 
and RBV is a plausible option. A regimen including two DAAs 
from separate classes (a NS5B inhibitor, a NS5A inhibitor, or a sec-
ond-generation NS3/4A protease inhibitor) could also be used to 
eradicate chronic HCV genotype 4. When physicians want to 
reduce the chance of virological relapse, RBV could be added to the 
regimen, provided that patients are able to tolerate this.
Decompensated cirrhosis
In general, patients with decompensated cirrhosis (Child-Pugh B/C) 
have lower response rates than patients with compensated cirrho-
sis (Child-Pugh A)46. Reasons for these lower response rates may 
include reduced drug delivery due to shunting leading to HCV 
reservoirs, altered drug metabolism and uptake due to impaired 
liver synthetic function, or impaired immune responses which are 
present in cirrhotic patients47.
Obviously, among patients with decompensated cirrhosis, the IFN-
free regimens are far better tolerated as compared to the PegIFN 
and RBV combination therapy, which has been the standard of care 
for the last 15 years. However, as more real-world data are emerg-
ing, safety issues regarding the use of DAAs among those patients 
with the most advanced liver disease have arisen. Two patients 
with hepatic decompensation developed severe drug-induced liver 
injury leading to death and liver transplantation. Both patients were 
treated with sofosbuvir, a NS5A inhibitor, and RBV48. A recent 
study by Welker et al. described the occurrence of lactate acido-
sis among patients treated with sofosbuvir-based regimens, with 
or without the addition of RBV49. Whether the clinical deteriora-
tion could be attributed to the use of DAAs or RBV or whether 
this is merely in line with the poor natural history of patients with 
decompensated cirrhosis remains a matter of debate. Likewise, the 
occurrence of hepatic decompensation during antiviral treatment 
has been reported for several treatment regimens, leading the FDA 
to discourage the use of dasabuvir, ombitasvir, and paritaprevir/ 
ritonavir for patients with decompensated liver disease50. Also, 
because of the real-world safety issues which were encountered 
with the first-generation protease inhibitors telaprevir and bocepre-
vir among patients with cirrhosis and low platelets or low albumin 
levels, one could argue that protease inhibitors may not represent 
an ideal class of DAAs for those with the most severe cirrhosis18. 
Simeprevir, a first-generation second-wave protease inhibitor, has 
actually never been registered for patients with decompensated cir-
rhosis. It is clear that further studies with a focus on the safety pro-
file of the IFN-free regimens among patients with decompensated 
liver disease are urgently needed. It would be highly relevant to 
be able to predict which of these patients can and cannot be safely 
treated with the IFN-free regimens.
Resistance-associated variants
The high efficacy of IFN-free regimens will lead to high rates of 
SVR, even among the population that was difficult to treat and/or 
difficult to cure in the era of IFN-based therapy. However, as pointed 
out earlier, lower response rates were observed among patients with 
advanced liver disease. The emergence of RAVs seems a relevant 
factor in case antiviral therapy is not successful. Although hetero-
geneous methods were used to detect RAVs, it has been estimated 
that 53–91% of patients with virological relapse harbor HCV iso-
lates that are resistant to one, two, or three DAAs51. The presence 
of RAVs before IFN-free treatment initiation could be an important 
cause of virological failure as well, and fuels the ongoing debate 
of whether we should perform pretreatment viral sequencing. 
Relevant in this respect is that the second-generation DAAs, which 
are coming shortly, are thought to have a higher genetic barrier to 
resistance. Another option to overcome the RAVs are the advanced 
cellular drugs that target the host factors involved in the HCV life 
cycle, which have the general advantage of being pan-genotypic. 
Silencing of miR-122 in vitro showed remarkable inhibition of 
HCV replication and led to the possibility of targeting miR-122 as 
an antiviral strategy28,52. Other possible options include the HCV 
entry inhibitors erlotinib and dasatinib, or the cyclophilin inhibitor 
alisporivir27,53. In combination with DAAs, the drugs targeting host 
factors could be effective, especially for those patients with resist-
ant viral strains. Still, in order to globally eradicate HCV, an effec-
tive vaccine seems necessary54.
Clinical relevance of successful antiviral therapy
In parallel with the impressive development of highly potent 
and well-tolerated DAAs, various cohort studies increased our 
understanding of the clinical relevance of these new drugs. Over 
the last couple of years, many researchers have published results 
that indicate that patients who attain SVR have a beneficial clini-
cal outcome in terms of both liver-related and liver-unrelated end-
points. The growing body of evidence in favor of SVR is, obviously, 
relevant for patients and physicians. However, it is also very much 
needed for policy-makers who need to decide on the reimbursement 
of the highly effective but costly IFN-free regimens.
Liver histology
In contrast to what was believed during the largest part of the 
last century, it is now widely accepted that hepatic fibrosis can 
regress in cases where the underlying cause of liver damage is 
adequately treated. Chronic HCV infection is probably the liver 
disease in which this is best documented. The largest histological 
study in which patients underwent a second liver biopsy 24 weeks 
after cessation of antiviral therapy indicated that, on average, the 
degree of hepatic fibrosis regressed among those with SVR and 
was rather stable among those without SVR55. The most impres-
sive result of this study, however, was that 75 of the 153 patients 
with cirrhosis before therapy no longer scored a METAVIR F4 in 
their post-treatment liver biopsy. Yet, from a previous study from 
Japan, we already learned that regression of hepatic fibrosis is 
likely to take more time56. Shiratori et al. included 593 patients in 
whom the time to the post-treatment liver biopsy ranged from 1 to 
10 years. Among those with SVR, the authors found that regres-
sion of fibrosis was more pronounced in cases where the biopsy 
was repeated after more than 3 years of follow-up. Still, even in 
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cases with much longer follow-up, histological studies have been 
unable to show that all HCV-infected patients with cirrhosis who 
attained SVR improve their METAVIR F4 score. The concept of a 
point of no return with respect to the extent of liver damage seems 
plausible, especially because the vascular abnormalities within a 
cirrhotic liver have never been shown to improve, and shunting of 
blood through vascularized portacaval septa can lead to hypoper-
fusion of liver parenchyma, with hypoxemia as a contributing factor 
for hepatic inflammation and fibrosis57–59. On the other hand, the 
semi-quantitative fibrosis scores may also be somewhat too crude 
to appreciate all histological improvements following the eradica-
tion of HCV infection. Indeed, a recent study assessed the change 
in the total area of fibrosis among 38 Italian patients with cirrho-
sis who attained SVR60. Among the minority (39%), in whom the 
METAVIR F4 score was not reduced after a median duration of 
5.6 years in between both liver biopsies, the total area of hepatic 
fibrosis was still significantly reduced. While the discussion on 
whether cirrhosis is reversible is ongoing, it may actually be more 
relevant to consider the relationship between HCV eradication and 
the clinical sequelae of cirrhosis61.
Liver-related morbidity and mortality
Most of the Western studies that assessed the association between 
HCV eradication and hepatic decompensation or HCC have solely 
included patients with advanced liver disease, who are most at risk 
for these cirrhosis-related complications. However, as we have long 
depended on IFN-based treatment regimens, these studies predomi-
nantly included cirrhotic patients with relatively favorable charac-
teristics. Veldt et al. were one of the first groups to show that the 
incidence in liver failure was markedly reduced among patients 
with chronic HCV infection and advanced liver fibrosis who 
attained SVR62. Interestingly, this beneficial outcome was apparent 
immediately upon HCV clearance. Hereafter, larger studies with 
longer follow-up duration not only confirmed these results but also 
showed a significant association between SVR and a reduced occur-
rence of HCC, with strong hazard ratios (HRs) adjusted for many 
potential confounders63–65. In a recent meta-analysis, in which the 
results of all available cohort studies among patients with advanced 
liver disease were pooled, the results indicated that within this 
population the HR of SVR for the occurrence of HCC was 0.23 
(95% confidence interval [CI] 0.16–0.35)66. Combining studies that 
included patients with all stages of fibrosis resulted in a pooled HR 
of 0.24 (95% CI 0.18–0.31) regarding SVR and HCC occurrence, 
although these studies were mostly performed in Japan, where the 
incidence of HCC is substantially higher. Considering the poten-
tial benefits of SVR on these cirrhosis-related morbidities, it is not 
surprising that patients with cirrhosis who clear their chronic HCV 
infection have a reduced liver-related mortality65,67. Still, it is note-
worthy that patients with advanced liver disease are not free from 
cirrhosis-related complications following HCV eradication. A com-
bined cohort including 1000 patients with advanced liver fibrosis 
and IFN-induced SVR showed that the annual risk of HCC remains 
at about 1% following HCV eradication in patients with cirrhosis68. 
The risk of HCC depends on age, the presence of diabetes melli-
tus, and laboratory markers of liver disease severity. One may thus 
expect a rising incidence of HCC following successful antiviral 
therapy in the era of DAAs, which will enable older patients with 
more advanced liver disease to attain SVR.
Extrahepatic consequences
While a large number of studies indicated potential liver-related 
benefits of SVR, more recent efforts have focused on the asso-
ciation between antiviral therapy and extrahepatic disease. With 
respect to patient-reported outcomes, eradication of HCV infection 
decreases both the frequency and the severity of fatigue8. This may 
be an important reason for the improved HRQoL which has been 
observed upon SVR69. Although difficult to quantify in daily prac-
tice, these effects are probably more directly noticeable for patients 
and their health-care providers than the prevention of future clinical 
complications.
Even a few years ago, it was reported that the risk of diabetes mel-
litus is about three times lower among patients with SVR as com-
pared to patients without SVR70. The deteriorating consequences 
of diabetes mellitus are diverse but surely include renal failure and 
cardiovascular events. A reduced incidence of both of these solid 
endpoints in cases of antiviral therapy use was recently shown in 
a nationwide cohort study from Taiwan, in which 12,384 treated 
patients and 24,768 propensity score-matched untreated controls 
were included. The cumulative 8-year incidences of end-stage renal 
disease (0.15% vs. 1.32%), acute coronary syndrome (2.21% vs. 
2.96%), and ischemic stroke (1.31% vs. 1.76%) were significantly 
lower among treated as compared to untreated patients (p<0.05 
for all), and the effect of antiviral therapy remained statistically 
significant in multivariate analysis71. These findings were immedi-
ately confirmed, and assigned to SVR, in a large population-based 
study which is expected to include about 80% of all IFN-treated 
chronic HCV-infected patients in Scotland72. Apart from diabetes 
mellitus, we were recently presented with another possible explana-
tion for these findings, as Gragnani et al. showed that HCV eradi-
cation led to the disappearance of cryoglobulinemia and resolved 
manifestations of the mixed cryoglobulinemia syndrome in nearly 
all patients73. Other potential extrahepatic benefits of SVR that have 
been presented within recent years include a reduced occurrence of 
malignant lymphomas and reduced hospitalization because of acute 
alcohol intoxication or violence-related injuries72,74. Through these 
effects on extrahepatic morbidity, patients with SVR have not only 
a reduced liver-related mortality but also a reduced liver-unrelated 
mortality72,75.
All-cause mortality
The most important new insights with regard to the clinical ben-
efit of antiviral therapy probably concern the association between 
SVR and a prolonged overall survival as the most definitive clinical 
endpoint. In 2011, Backus et al. were the first to show that SVR 
was statistically significantly associated with a reduced all-cause 
mortality (HR 0.70, 0.64, and 0.51 for HCV genotype 1, 2, and 3, 
respectively) in a large cohort of 16,864 patients with chronic HCV 
infection who were followed for a median duration of 3.8 years76. 
However, these results were derived from the specific patient 
population of American veterans, among which there is substantial 
comorbidity, risk behavior, and a rather high mortality rate. Another 
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report extended this finding to the general HCV-infected patient 
population with advanced liver disease67. Among the 530 patients 
with chronic HCV infection and advanced liver fibrosis who were 
followed for a median of 8.4 years, the cumulative 10-year over-
all survival was 91% among those with SVR, versus 74% among 
those without SVR (HR 0.26, 95% CI 0.14–1.49). In contrast to 
those who were unsuccessfully treated, patients with SVR had a 
survival rate that was comparable to that of the age- and sex-matched 
general population77. Importantly, in both reports, the HR of SVR 
for all-cause mortality was extensively adjusted for baseline char-
acteristics known to influence both the chance of successful IFN 
therapy and the long-term clinical outcome. Various representable 
cohorts have confirmed the strong association between SVR and 
reduced all-cause mortality hereafter72,78. The pooled HR of SVR 
was 0.50 (95% CI 0.37–0.76) based on all studies which did not 
specifically include patients with advanced fibrosis and 0.26 (95% 
CI 0.18–0.37) when only studies among those with advanced liver 
disease were considered79.
Decompensated cirrhosis
The above-described studies, which suggest a clinical benefit 
of SVR, were performed among patients treated with IFN-based 
regimens, so that even those included with cirrhosis had relatively 
favorable baseline characteristics. Indeed, in the IFN era, patients 
with decompensated cirrhosis were frequently withheld from anti-
viral therapy but were also unlikely to attain SVR if treatment was 
initiated. Consequently, the clinical relevance of attaining SVR is 
largely unknown apart from the fact that achievement of SVR would 
be desirable to prevent HCV recurrence in cases of liver transplan-
tation. Because of the beneficial safety profile of the DAAs, our 
experience with antiviral therapy in patients with chronic HCV 
infection and decompensated cirrhosis is increasing rapidly. Still, 
because these therapeutic options have just surfaced, studies with 
sufficient follow-up to assess the true clinical impact of IFN-free 
therapy among the patients with the most advanced liver disease 
have to be awaited. In the meantime, several interesting observa-
tions in the short term have been presented, which focus on the 
Model for End-Stage Liver Disease (MELD) score. Deterding et al. 
treated 34 HCV-infected patients with Child-Pugh B/C with various 
IFN-free regimens. At 12 weeks post-treatment, the MELD score 
improved in 68%, remained stable in 23%, and worsened in 10% 
of patients80. Based on the first experiences in England, Foster et al. 
reported the change in MELD score 4 weeks after the cessation 
of DAA therapy81. Of the 220 patients, 105 (47.7%) had no sig-
nificant change in MELD score; in 92 (41.8%) patients, MELD 
score improved by ≥2 points; and in 23 (10.5%) patients, MELD 
score worsened by ≥2 points. Additional analyses indicated that the 
MELD score more frequently improved rather than declined among 
younger patients (<65 years) and patients with a high albumin level 
(>35 g/L). Still, MELD improvements are mostly moderate, so the 
important question of whether liver transplantation can really be 
averted remains. If not, the slight improvement in MELD score may 
actually negatively impact the patient’s chances on the waiting list. 
Because clinical trials showed excellent SVR rates with IFN-free 
therapy among liver transplant recipients with chronic HCV infec-
tion, it may be questioned whether patients with decompensated 
cirrhosis should be treated before or after transplantation82,83. Within 
the next 2 years, more data will hopefully become available, which 
may be able to guide this decision for the individual patient. Pref-
erably, patients with decompensated cirrhosis should therefore be 
treated within registry studies during the upcoming years.
Conclusion
The implementation of IFN-free treatment regimens has broadened 
the horizon for patients with chronic HCV infection tremendously. 
Within a timeframe of 5 years, important treatment developments 
resulted in near-perfect SVR rates, even among patients with the 
most advanced liver disease. As successful antiviral therapy may 
be lifesaving, these developments were long awaited. Some hurdles 
have to be taken, however, before the health burden of this chronic 
disease can truly be reduced. For instance, the access to DAAs 
needs to be broadened so that patients can be treated regardless of 
the severity of hepatic fibrosis. Reducing the costs of these drugs 
probably remains a key factor before this goal can be achieved. As 
developments are still ongoing, prices will hopefully fall as a result 
of mutual competition. Also, it is important to increase the number 
of patients who are diagnosed, as the majority of patients are cur-
rently unaware of their chronic viral hepatitis. Pan-genotypic regi-
mens are currently being evaluated in phase III trials as well, which 
will hopefully simplify antiviral therapy even more. Until that time, 
treatment selection is required and prioritizing treatment is needed 
to limit the economic burden. Treating those with advanced hepatic 
disease first seems reasonable, but remains far from ideal.
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